Betcha Theravance doesn't make it. The window for Wave II seems to be pretty well closed now:
>>SOUTH SAN FRANCISCO, Calif., June 17 /PRNewswire/ -- CoTherix, Inc. has decided to postpone its initial public offering of common stock. Based on adverse market conditions, CoTherix has determined that it is not advisable at this time to proceed with the proposed offering.
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. CoTherix's lead product candidate, Ventavis(R), is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins. CoTherix is developing Ventavis for the treatment of pulmonary arterial hypertension, a highly debilitating disease characterized by severe constriction of the blood vessels of the lungs. Ventavis is currently marketed in various European countries by Schering AG. CoTherix licensed the exclusive U.S. rights to Ventavis from Schering AG in October 2003. CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis(R) is a trademark of Schering AG, Germany.
CoTherix, Inc.
CONTACT: Christine Gray-Smith of CoTherix, Inc., +1-650-808-6500 orcgraysmith@cotherix.com; or, Investors, Nina Ferrari, +1-415-318-4286 orferrarin@fleishman.com, or, Media, Kate Brinks, +1-415-318-4156 orbrinksk@fleishman.com, both for CoTherix, Inc.
Web site: cotherix.com <<
And this, mind you, is a company sporting the oh so fashionable business model involving the licensing of late stage or even marketed compounds, that gets VC breathing heavily.
Amazing a company like Cytokinetics made it out at all.
BTW, as an addendum to my previous post, I also think STRS is interesting. As charlyt asks, can they market their newly approved PPI? I suspect that launch and earnings related buying opportunities will present themselves.
Cheers, Tuck |
